Skip to main content
. Author manuscript; available in PMC: 2012 Jun 1.
Published in final edited form as: Eur J Cancer. 2011 Mar 31;47(9):1380–1388. doi: 10.1016/j.ejca.2011.03.001

Table 4.

Relative risks for the prediction of physician health care and dental care.

General Healthcare General Survivor Care Risk based survivor care Dental Care
RR 95% CI p RR 95% CI p RR 95% CI p RR 95% CI p
Age -- -- -- -- -- -- -- -- -- 1.01 1.01–1.01 0.0002
Sex
 Male (ref) 1.0 1.0 1.0 1.0
 Female 1.14 1.11–1.71 <0.0001 1.48 1.35–1.62 <0.0001 1.35 1.25–1.46 <0.0001 1.08 1.05–1.11 <0.0001
Insurance
 No (ref) 1.0 1.0 1.0 1.0
 Yes 1.30 1.21–1.39 <0.0001 2.24 1.82–2.75 <0.0001 2.65 2.13–3.30 <0.0001 1.57 1.43–1.72 <0.0001
Household Income
 <20,000 (ref) 1.0 -- -- -- -- -- -- 1.0
 ≥20,000 1.08 1.03–1.13 0.003 -- -- -- -- -- -- 1.16 1.09–1.24 <0.0001
BMI
 Normal Range (ref) -- -- -- -- -- -- -- -- -- 1.0
 Obese -- -- -- -- -- -- -- -- -- 0.92 0.88–0.96 <0.0001
 Overweight -- -- -- -- -- -- -- -- -- 0.99 0.96–1.03 0.59
 Underweight -- -- -- -- -- -- -- -- -- 1.01 0.95–1.07 0.77
Diagnoses
 Other -- -- -- -- -- -- -- -- -- 1.0
 Leukemia -- -- -- -- -- -- -- -- -- 0.98 0.95–1.00 0.07
 CNS Tumors -- -- -- -- -- -- -- -- -- 1.06 1.03–1.09 <0.0001
Neurocognitive Problems
 No Problems (ref) -- -- -- 1.0 1.0
 Organization -- -- -- -- -- -- -- -- -- 0.92 0.88–0.97 0.002
 Task Efficiency -- -- -- 1.20 1.10–1.30 <0.0001 -- -- -- -- -- --
Antidepressant Use
 No -- -- -- -- -- -- 1.0 -- -- --
 Yes -- -- -- -- -- -- 1.20 1.13–1.28 <0.0001 -- -- --

Note: -- represents variables that did not remain in the model after the backward selection. Variables significant following Bonferroni adjustment for multiple comparisons are highlighted with bold font. Age used as a continuous variable (years). BMI classifications defined as: underweight = BMI<18.5, normal weight = BMI 18.5–24.9; overweight = BMI 25–29.9; obese = BMI≥30. Other diagnosis category represents a combined group of Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Wilm’s Tumor, Neuroblastoma, Soft tissue sarcoma, Bone cancer. Neurocognitive problems defined as a level of negative symptoms reported in ≤ 10% of standardization samples.